(Total Views: 764)
Posted On: 11/28/2025 8:44:03 PM
Post# of 158771
"I want to know how PDL-1 levels between tumor biopsy and liquid biopsy typically correlate."
In the Creatv Bio process, which filters out blood cells and reveals what's left, the liquid biopsy is essentially the tumor biopsy. An article in biztechoutlook.com explains:
"Unlike many diagnostics that rely on genetic fragments, LifeTracDx captures actual tumor-associated cells from a standard blood draw. Using the CellSieve microfilters, which feature ultra-precise 7-micron pores, the test removes red and most white blood cells while trapping larger CTCs" (which are then examined under a microscope).
These CTCs include macrophages which have eaten chunks of the tumor. So that's how a blood draw can contain actual pieces of the tumor. Freaking amazing! The article continues with more details about Creatv Bio's discovery:
"While filtering blood from cancer patients, they captured many large, bizarre-looking cells which had never been documented with clinical utility in scientific literature. These were giant, polynucleated cells that exhibited strange shapes, some with long tails, others rod-shaped or oval...
These CAMLs, typically ranging from 25-300 microns, are formed when macrophages engulf cancerous material. Importantly, they have been observed in over 30 different cancer types, even at Stage 1. They have never been detected in healthy individuals. This makes CAMLs not only a potent diagnostic marker but a potential game-changer for early detection."
biztechoutlook.com/creatv-bio-transforming-diagnosis-through-a-simple-blood-test/
We are very fortunate to be collaborating with CreatvBio. Early detection and a CCR5 inhibitor that cranks up the immune response with no serious adverse events--that suggests a whole new way to approach first-line solid tumor cancer that is chemo and surgery-free. (At least CCR5+ cancers... for now).
Imagine--if caught early enough, the immune system--juiced with leronlimab-- shuts down RANTES signaling and controls tumor growth and metastasis without the need for surgery. And then, as needed for second-line or post-surgical cases, the next-generation PD1/PD-L1 inhibitors, combined with leronlimab, do their thing and finish the job. I can't believe I'm saying this... but we are that close to managing if not curing CCR5+ cancer! At the very least, catching cancer before symptoms, and treating it safely without chemo or surgery. With ICIs left as a 3rd or 4th line for those who progress, or whose cancer wasn't caught early enough... That is a solid tumor protocol I could live with!
It strikes me that if we could figure out how to organically make all cancers express CCR5... well, that would take care of that! Perhaps that is the next big thing... after the breakthrough in PD-L1 upregulation via leronlimab settles in to clinical practice. That would be a useful question for AI...
But right now, in the cancer space, all Biospace and Fierce Biotech can talk about are ADCs and TIGITs and who is going to take Keytruda's crown. Shame on them--they act like Big Pharma lackeys, rather than providing critical, independent-minded assessment of what's going on in the field...
Well, perhaps new and granular data from Creatv/Cytodyn in the next few months will get a mention out of them. I'd like to see Cytodyn stack a few market-moving announcements in a row, and see if the share price sizzles. I'd say we are due...
In the Creatv Bio process, which filters out blood cells and reveals what's left, the liquid biopsy is essentially the tumor biopsy. An article in biztechoutlook.com explains:
"Unlike many diagnostics that rely on genetic fragments, LifeTracDx captures actual tumor-associated cells from a standard blood draw. Using the CellSieve microfilters, which feature ultra-precise 7-micron pores, the test removes red and most white blood cells while trapping larger CTCs" (which are then examined under a microscope).
These CTCs include macrophages which have eaten chunks of the tumor. So that's how a blood draw can contain actual pieces of the tumor. Freaking amazing! The article continues with more details about Creatv Bio's discovery:
"While filtering blood from cancer patients, they captured many large, bizarre-looking cells which had never been documented with clinical utility in scientific literature. These were giant, polynucleated cells that exhibited strange shapes, some with long tails, others rod-shaped or oval...
These CAMLs, typically ranging from 25-300 microns, are formed when macrophages engulf cancerous material. Importantly, they have been observed in over 30 different cancer types, even at Stage 1. They have never been detected in healthy individuals. This makes CAMLs not only a potent diagnostic marker but a potential game-changer for early detection."
biztechoutlook.com/creatv-bio-transforming-diagnosis-through-a-simple-blood-test/
We are very fortunate to be collaborating with CreatvBio. Early detection and a CCR5 inhibitor that cranks up the immune response with no serious adverse events--that suggests a whole new way to approach first-line solid tumor cancer that is chemo and surgery-free. (At least CCR5+ cancers... for now).
Imagine--if caught early enough, the immune system--juiced with leronlimab-- shuts down RANTES signaling and controls tumor growth and metastasis without the need for surgery. And then, as needed for second-line or post-surgical cases, the next-generation PD1/PD-L1 inhibitors, combined with leronlimab, do their thing and finish the job. I can't believe I'm saying this... but we are that close to managing if not curing CCR5+ cancer! At the very least, catching cancer before symptoms, and treating it safely without chemo or surgery. With ICIs left as a 3rd or 4th line for those who progress, or whose cancer wasn't caught early enough... That is a solid tumor protocol I could live with!
It strikes me that if we could figure out how to organically make all cancers express CCR5... well, that would take care of that! Perhaps that is the next big thing... after the breakthrough in PD-L1 upregulation via leronlimab settles in to clinical practice. That would be a useful question for AI...
But right now, in the cancer space, all Biospace and Fierce Biotech can talk about are ADCs and TIGITs and who is going to take Keytruda's crown. Shame on them--they act like Big Pharma lackeys, rather than providing critical, independent-minded assessment of what's going on in the field...
Well, perhaps new and granular data from Creatv/Cytodyn in the next few months will get a mention out of them. I'd like to see Cytodyn stack a few market-moving announcements in a row, and see if the share price sizzles. I'd say we are due...
(25)
(0)
